A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis
About the study
The purpose of this study is to evaluate clinical effectiveness and safety of BMS-986322 in participants with moderate-to-severe psoriasis.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Diagnosis of plaque psoriasis (PsO) for ≥ 6 months
- Body mass index 18 to 40 kg/m^2 and total body weight > 50 kg (110 lbs)
- Deemed by Investigator to be eligible for phototherapy or systemic therapy
- Psoriatic plaques must cover ≥ 10% of body surface area at baseline
- Psoriasis Area and Severity Index (PASI) score ≥ 12 and static Physician Global Assessment (sPGA) ≥ 3 at baseline
EXCLUSION CRITERIA
Exclusion Criteria:
- Diagnosis of non-plaque psoriasis (guttate, inverse, pustular, erythrodermic)
- Diagnosis of uveitis, inflammatory bowel disease, or other immune-mediated conditions that are commonly associated with PsO for which a participant requires current systemic immunosuppressant medical treatment
- Any significant acute or chronic medical illness
Other protocol-defined inclusion/exclusion criteria apply
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study Details
Contition
Psoriasis
Age (in years)
18 - 70
Phase
PHASE2
Participants Needed
109
Est. Completion Date
Aug 6, 2024
Treatment Type
INTERVENTIONAL
Sponsor
Bristol-Myers Squibb
ClinicalTrials.gov NCT Identifier
NCT05730725
Study Number
IM032041
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?